FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.
Read original at benzingaStocks · News reference
Mizuho Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $120
Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Market Outperform and raises the price target from $115 to $120.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 6:30 PM
- Checked
- Jul 15, 2026, 6:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
Read original at benzingaLantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate
Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.30 by 19.23 percent. This is a 1.27 percent decrease over earnings of $1.57 per share from
Read original at benzingaHalper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.
Read original at globenewswire-inc